v3.26.1
Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
 3 Months Ended 6 Months Ended
May 21, 2024
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]              
Stock-based compensation expense $ 600,000 $ 1,627,909   $ 1,524,943   $ 3,264,583 $ 3,217,210
Depreciation and amortization   84,454   84,527   165,856 169,788
Net loss   (17,270,427) $ (13,460,895) (14,433,881) $ (15,046,132) (30,731,322) (29,480,012)
Reportable Segment              
Segment Reporting [Line Items]              
Non-program expenses   1,751,748   1,583,015   3,221,300 2,787,399
Employee-related costs   6,082,231   4,944,540   12,150,168 10,323,479
Stock-based compensation expense   1,627,909   1,524,943   3,264,583 3,217,210
Depreciation and amortization   84,454   84,527   165,856 169,788
Other segment items   (1,729,982)   (324,013)   (3,604,121) (762,532)
Net loss   17,270,427   14,433,881   30,731,321 29,480,012
Reportable Segment | Atebimetinib (IMM-1-104)              
Segment Reporting [Line Items]              
Program expenses   7,262,339   5,169,330   11,317,597 9,427,266
Reportable Segment | Envometinib (IMM-6-415)              
Segment Reporting [Line Items]              
Program expenses   18,255   278,612   22,600 1,902,367
Reportable Segment | Other programs              
Segment Reporting [Line Items]              
Program expenses   $ 2,173,473   $ 1,172,927   $ 4,193,338 $ 2,415,035